Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| National Institute of Mental Health (NIMH) | NIH |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such Adolescent Trials Network (ATN) research activities.
This phase will describe specific locations within high-risk areas where youth, ages 12-24, spend time. HIV risk behaviors, social networking patterns and HIV prevalence among youth at these venues will be assessed by administering anonymous computerized interviews to eligible and willing youth. This information will be shared with community partners during scheduled working group meetings.
This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such ATN research activities.
During this phase, each ATN site will gather additional information within high-risk areas and solicit community partner input to ultimately pinpoint the specific locations where at-risk youths, ages 12-24, may be recruited for interventions. This will be done by the following methods:
Venues will be identified by HIV+ youth at the ATN site by participation in an anonymous computerized interview. Site staff will then perform brief venue interviews (BVIs) at selected venues to assess the potential yield of youths 12-24 years old. Community partners will also provide the site staff with information on known high-risk venues. High-risk venues will further be identified by the results of anonymous computerized interviews and HIV assays obtained from eligible and willing youth participants at the venues. The interviews will gather information on HIV risk behaviors, social networking patterns and HIV prevalence among youths at these venues. This information will be shared with community partners during scheduled working group meetings.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIV Infected Youth in Treatment/Care | HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site). | ||
| BVI Individuals | Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours). | ||
| HIV Serosurvey Individuals | HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site).. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Ascertain specific community venues where at-risk youth can be recruited for interventions within the high-risk areas identified in the first Phase of the study | The outcome measure will be assessed using results from: (a) Phase I mapping; (b) Phase II interviews with HIV-infected youth; and (c) Phase II Brief Venue Interviews (BVIs). Input from community partners and ethnographic procedures will add critical information. | One time assessment at 10 months |
| Describe HIV risk behaviors of adolescents and young adults recruited from targeted venues | The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown. | One time assessment at 10 months |
| Describe social networks of adolescents and young adults recruited from targeted venues | The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown. | One time assessment at 10 months |
| Describe HIV seroprevalence of adolescents and young adults recruited from targeted venues | The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown. | One time assessment at 10 months |
| Assess the characteristics of the community-researcher partnerships | The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept. | One time assessment at 10 months |
| Assess quality of the community-researcher partnerships |
Not provided
Not provided
Inclusion Criteria:
Index Subjects:
BVI subjects:
HIV Serosurvey subjects at the venues:
Exclusion Criteria:
Not provided
Not provided
HIV infected youth, ages 12 through 24 years old, in treatment/care at each of the 15 ATN sites will be interviewed using ACASI technology to reveal possible venues where youth at high risk for acquiring the HIV may be found. Individuals approached at 3-5 of these identified venues who appear to be 12 through 24 years will be offered a brief venue interview. Anonymous HIV serosurvey (ACASI and HIV-Ab assay) will be administered to 20-30 young women at 2-3 identified high-risk venues, and 20-30 young men at 2-3 identified high-risk venues, who provide verbal confirmation of being 12 through 24 years old, and whose HIV status is unknown to the site staff.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan Ellen, MD | Johns Hopkins Medical Center | Study Chair |
| Ligia Peralta, MD | Division of Adolescent & Young Adult Medicine University of MD, Medical School | Principal Investigator |
| Donna Futterman, MD | Montefiore Medical Center | Principal Investigator |
| Marvin Belzer, MD | Childrens Hosp of Los Angeles, Division of Adolescent Medicine | Principal Investigator |
| Bret Rudy, MD | Children's Hospital of Philadelphia | Principal Investigator |
| Larry D'Angelo, MD | Children's National Research Institute | Principal Investigator |
| Cathryn Samples, MD | Boston Children's Hospital | Principal Investigator |
| Lisa Henry-Reid, MD | John H. Stroger Jr. Hospital and the CORE Center | Principal Investigator |
| Ana Puga, MD | Children's Diag. and Treatment Ctr of Ft. Lauderdale, FL |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Childrens Hospital of Los Angeles | Los Angeles | California | 90054 | United States | ||
| UCSD Mother, Child & Adolescent HIV Program |
Not provided
| Label | URL |
|---|---|
| Website for the Adolescent Trials Network for HIV/AIDS Interventions | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept. |
| One time assessment at 10 months |
| Assess outcomes of the community-researcher partnerships | The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept. | One time assessment at 10 months |
| Lawrence Friedman, MD | University of Miami, School of Medicine, Div of Adolescent Medicine | Principal Investigator |
| Patricia Emmanuel, MD | University of South Florida, Peds Div of Infectious Disease | Principal Investigator |
| Sue Ellen Abdalian, MD | Tulane Medical Center | Principal Investigator |
| Linda Levin, MD | Mount Sinai Adolescent Health Center | Principal Investigator |
| Irma Febo, MD | University of Puerto Rico Medical Sciences Campus | Principal Investigator |
| Stephen A Spector, MD | UCSD Mother, Child, & Adolescent HIV Program | Principal Investigator |
| Rolando M Viani, MD | UCSD Mother, Child, & Adolescent HIV Program | Principal Investigator |
| Barbara Moscicki, MD | UCSF, Division of Adoles. Med | Principal Investigator |
| Coco Auerswald, MD | UCSF, Division of Adoles. Med | Principal Investigator |
| San Diego |
| California |
| 92103 |
| United States |
| Univ of Califormia at San Francisco | San Francisco | California | 94143 | United States |
| Children's Hospital National Medical Center | Washington D.C. | District of Columbia | 20010 | United States |
| Children's Diag. and Treatment Center | Fort Lauderdale | Florida | 33301 | United States |
| University of Miami | Miami | Florida | 33101 | United States |
| USF Peds Div. of Infectious Disease | Tampa | Florida | 33606 | United States |
| Stroger Hospital of Cook County | Chicago | Illinois | 60612 | United States |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | United States |
| University of Maryland | Baltimore | Maryland | 21201 | United States |
| Childrens' Hospital of Boston | Boston | Massachusetts | 02115 | United States |
| Mount Sinai Medical Center | New York | New York | 10128 | United States |
| Montefiore Medical Center, Adolescent AIDS Program | The Bronx | New York | 10467 | United States |
| Children's Hopsital of Philadelphia | Philadelphia | Pennsylvania | 19104 | United States |
| University Pediatric Hospital | San Juan | 00936 | Puerto Rico |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided